# Hebei Senlang Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hebei-senlang-biotechnology-co

- Industry: Biotechnology
- Headquarters: Shijiazhuang, China
- Website: www.senlangbio.com
- Latest round: Series B (Dec 7, 2018)
- Investors on record: 1

## About

Established in 2016 and based in Hebei, China, Hebei Senlang Biotechnology Co.,Ltd operates as a developer of tumor cell immunotherapy. The company's Founder and CSO, Jianqiang Li has over 20 years of experience in immunology and cell therapy, published 13 papers in Nature Medicine, Blood, and Journal of Immunology. As of 2022, the company has 160 employees.

Its cell therapy technology platforms include chimeric antigen receptor (CAR) T-cells (CAR-T), allogeneic CAR Gamma Delta T-cells (CAR-GDT), and armored tumor-infiltrating lymphocytes (armTILs). Its CAR-T cell therapy portfolio consists of multiple autologous and allogeneic candidates. Its CAR-T candidates can against relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), T-cell ALL (T-ALL), non-Hodgkin's lymphoma(NHL), and T-cell lymphoblastic lymphoma.

## Funding rounds

- Series B, Dec 7, 2018 — Guo Chuang Investment

## Investors

- Guo Chuang Investment (https://capitalatlas.ai/funds/guo-chuang-investment) — Series B